David Sinclair/X
May 4, 2026, 17:00
David Sinclair: NMN Modulates Immune Response in Antibody-Mediated Bleeding Disorder
David Sinclair, Author and Host of Lifespan, shared a post on X about a recent article by Huiyuan Li et al., published in Nature, adding:
”New Clinical Trial Result:
NMN suppresses harmful antibody-driven immune attacks to alleviate a common bleeding disorder. Authors suggest it may help other autoimmune diseases like lupus and rheumatoid arthritis.”
Title: Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial
Authors: Huiyuan Li, Yuan Xu, Yunfei Chen, Lulu Ji, Yanmei Xu, Wenting Zheng, Ting Sun, Rongfeng Fu, Xiaolei Pei, Xiaofan Liu, Feng Xue, Wei Liu, Wentian Wang, Ying Chi, Renchi Yang, Jun Wei, Lei Zhang
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 17, 2026, 17:27John Strouse: Building Standards for Whole-Person Sickle Cell Care Through Collaboration
-
Oct 17, 2026, 17:20Jean-Jacques Kiladjian: Exploring the Future of Polycythemia Vera Treatment at MPN Horizons 2026
-
Oct 17, 2026, 17:10Habib Bennaceur: Strengthening Collaboration in Haemophilia, Sickle Cell Disease and Thalassaemia in India
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland
-
Oct 17, 2026, 16:48Kalyan Roy: Enhancing Patient Experience Through Learning and Collaboration
-
Oct 17, 2026, 16:43Wilfried Dinh: Antiplatelet Therapy in 2026: Duration is Becoming a Dynamic Decision
-
Oct 17, 2026, 16:37Ian Setchfield: Dr. Evans Presents on Safe Anticoagulation Prescribing at East Kent Hospitals
-
Oct 17, 2026, 16:33Lewis Thomas: Connecting Through Shared Experiences at ASCAT 2026
-
Oct 17, 2026, 16:29Nilesh Jethwa: Yasmin Adverse Event Reports Exceed 23,000 Over Two-Year Period